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Abstract
Cowpea mosaic virus (CPMV) is a plant comovirus in the picornavirus superfamily, and is used for a wide variety of
biomedical and material science applications. Although its replication is restricted to plants, CPMV binds to and enters
mammalian cells, including endothelial cells and particularly tumor neovascular endothelium in vivo. This natural capacity
has lead to the use of CPMV as a sensor for intravital imaging of vascular development. Binding of CPMV to endothelial cells
occurs via interaction with a 54 kD cell-surface protein, but this protein has not previously been identified. Here we identify
the CPMV binding protein as a cell-surface form of the intermediate filament vimentin. The CPMV-vimentin interaction was
established using proteomic screens and confirmed by direct interaction of CPMV with purified vimentin, as well as
inhibition in a vimentin-knockout cell line. Vimentin and CPMV were also co-localized in vascular endothelium of mouse and
rat in vivo. Together these studies indicate that surface vimentin mediates binding and may lead to internalization of CPMV
in vivo, establishing surface vimentin as an important vascular endothelial ligand for nanoparticle targeting to tumors. These
results also establish vimentin as a ligand for picornaviruses in both the plant and animal kingdoms of life. Since bacterial
pathogens and several other classes of viruses also bind to surface vimentin, these studies suggest a common role for
surface vimentin in pathogen transmission.
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Introduction
Cowpea mosaic virus (CPMV) is a member of the comoviridae
family of plant viruses. The 31 nm-diameter capsid has a pseudo
T=3 symmetry composed of 3 beta-barrel domains formed from
2 capsid proteins, and is structurally related to animal picorna-
viruses that include such viruses as poliovirus, coxsackievirus, and
Theiler’s murine encephalomyelitis virus (TMEV) [1]. Within the
picornavirus-like superfamily these viruses also share a similar
genetic organization and along with CPMV are thought to derive
from a common ancestor [2,3]. The mechanisms of evolution of
the picorna-like viruses within the kingdoms of life, and possible
cross-kingdom transmission during evolution, are unknown.
In addition to its role as a plant pathogen, CPMV has received
recent attention as a nanoscale scaffold for the design of vaccines
and therapeutics [4–7]. The ability to generate nanoscale materials
that can specifically target and image sites of disease is an
important goal in biomedicine. A variety of nanoparticle strategies
have been developed for targeting and imaging in vivo including
antibodies [8], dendrimers [9], liposomes [10], nanoshells [11],
quantum dots [12], and viruses [13,14]. Viruses are particularly
suited for these applications because they are naturally designed
for efficient circulation and specific ligand-binding and cellular
internalization. Recently interest has turned toward self-assem-
bling plant viruses, bacteriophages [4], and protein cage [15]
architectures that can be adapted for in vivo targeting purposes
without the pathogenic properties of animal viruses. However
these viruses must generally be tailored to recognize their targets
using specific ligands.
As a nanoparticle, CPMV is a robust biomaterial that is
systemically bioavailable through both oral and intravenous
inoculation [16]. These properties have been integral to its use
as a vaccine platform [17–19]. CPMV has also been studied for
materials applications such as multilayer assembly and chemical
scaffolds [20]. Recent studies have also shown that CPMV can be
chemically modified with specific ligands to achieve tumor-specific
targeting [14]. Although the host range for CPMV replication is
restricted to plants, interestingly the unmodified CPMV capsid
also naturally interacts with mammalian cells. Intravital imaging
studies using fluorescently-labeled CPMV particles yielded high-
resolution images of normal and tumor vasculature in vivo [13].
These imaging studies showed that CPMV particles were readily
internalized in mouse and chick endothelial cells following
intravenous administration in living embryos, and this internali-
zation produced high-resolution images of vasculature in real-time
using epifluorescence microscopy [13]. Tumor neovasculature in
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internalization by arterial and venous vessels was also observed,
however the mechanism of uptake was unknown [13].
We subsequently determined that CPMV binding is mediated
by a specific interaction between CPMV and a surface-exposed,
non-glycosylated 54 kD binding protein that is present on a
variety of mammalian cells including human umbilical vein
endothelial cells (HUVEC) [21]. Since the interaction between
CPMV and the 54 kD protein correlated with such high-
resolution intravital vascular images, we reasoned that identify-
ing the 54 kD CPMV attachment protein would potentially
reveal a useful endothelial marker for vascular imaging. We also
hypothesized that understanding the mechanism of CPMV
attachment to mammalian cells would provide important
information regarding the relationships between plant and
animal picornaviruses. Thus the aim of this study was to identify
and characterize the 54 kD CPMV binding protein (CPMV-BP)
using proteomics, biochemical assays, flow cytometry, and
fluorescence confocal microscopy.
Results
To identify the 54 kD CPMV-BP, a proteomics study was
performed using liquid chromatography and tandem mass
spectrometry (LC-MS/MS). The 54 kD protein is found in the
plasma membrane-enriched fraction of cells, lacks N- and O-
glycosylation, and was identified by its ability to bind directly to
CPMV particles using a Virus Overlay Protein Blot Assay
(VOPBA) [21]. The VOPBA technique has identified many
high-affinity virus receptors including those for coronaviruses
[22,23], adenoviruses [24], and arenaviruses [25]. Mass spec-
trometry analysis focused first on enriched plasma membrane
proteins that co-migrated with the 54 kD band on SDS-PAGE;
this resulted in identification of 68 individual proteins (Table 1).
Surface biotinylation of cells, followed by isolation of enriched
plasma membranes and streptavidin-sepharose purification of
biotinylated proteins, separation on SDS-PAGE and VOPBA,
yielded a sample in the 54 kD range that was also analyzed by LC-
MS/MS and yielded 7 proteins (Table 1). The third approach
used the enriched plasma membrane fraction as starting material
(Figure 1A) followed by sequential column chromatography
(Figure 1B). Here the membrane fraction was first run over a
concanavalin A-sepharose column to remove glycoproteins, and
the flow-through fraction was bound to an affinity matrix that was
generated when surface lysine residues on purified CPMV
particles were directly conjugated to N-hydroxysuccinimidyl
ester-sepharose (CPMV-sepharose). The CPMV-bound sample
was washed several times, and then CPMV-sepharose beads were
pelleted by centrifugation and bound proteins separated on SDS-
PAGE (Figure 1C). Three bands were easily visible by SimplyBlue
(Invitrogen) staining, corresponding to the 54 kD CPMV-BP, the
42 kD large capsid subunit of CPMV, and the 24 kD small CPMV
capsid subunit. The 54 kD band was excised from the gel, digested
with trypsin, and analyzed by LC-MS/MS using nano-electro-
spray on a linear ion trap mass spectrometer (Figure 1D). In this
analysis two proteins were positively identified: vimentin and
keratin. Keratin is a common laboratory contaminant that is
isobaric with vimentin. Vimentin was also identified in all the
preceding mass spectrometry analyses (Table 1). A complete listing
of all proteins identified in each screen can be seen in Table S1.
Vimentin is a type III intermediate filament and a major
component of the cytoskeleton. Expressed in cells of mesenchymal
origin, vimentin plays a key role in intracellular dynamics and
architecture [26]. Vimentin encodes head, rod, and tail domains,
and these domains are identified based on sequence and function
[26]. Although it has long been considered a cytosolic protein,
surface-expressed forms of vimentin have recently been discovered
Author Summary
Cowpea mosaic virus (CPMV), a plant virus that does not
replicate in animals, is extensively used in material science
and nanobiotechnology. CPMV has been found to
specifically interact with mammalian cells after oral or
intravenous administration, as well as in intravital vascular
imaging studies that used a fluorescently modified form of
CPMV. Binding of CPMV to mammalian cells was shown to
be via a cell-surface binding protein (CPMV-BP). Herein we
identify this cell surface CPMV-BP through biochemical
analysis, live cell experiments, and animal models. We
found this surface exposed protein to be vimentin.
Vimentin is principally a cytoskeletal protein that functions
in the interior of cells to modulate architecture and
dynamics. Our results now indicate surface vimentin can
be used as a vascular endothelial marker and targeting
option on the exterior surface of these cells. This work also
unifies the relationship between CPMV and closely related
mammalian viruses such as poliovirus, Theiler’s murine
encephalomyelitis virus (TMEV), and coxsackie virus
through the collective use of vimentin during their
infectious cycle. Several other bacterial and viral patho-
gens use surface vimentin as an attachment receptor as
well, and this research may lead to the development of
broad-spectrum strategies to inhibit infection.
Table 1. Summary of proteomic analyses used for identifying CPMV-BP.
Proteomic
Analysis Description
Number of Proteins Identified
by .2 Peptides at 95%
Confidence Level
Peptides Identified
from Vimentin
% Sequence
Coverage
Confidence Level
of Vimentin ID
1 Enriched plasma membrane proteins
that co-migrated with 54 kD band
68 28 56% 100%
2 Surface proteins isolated through
biotinylation and co-migrated with
54 kD band
7 14 33% 100%
3 Enriched plasma membrane proteins
which were purified through sequential
column chromatography (Fig. 1) and
co-migrated with 54 kD band
2 2 7% 100%
doi:10.1371/journal.ppat.1000417.t001
Surface Vimentin-CPMV Interaction
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[27,28], activated macrophages [29], platelets [30], vascular
endothelial cells [31], brain microvascular endothelial cells [32],
Sezary T cells [33], and skeletal muscle cells [32]. The mechanism
by which vimentin reaches the cell surface, which domains are
exposed, and its function at the surface, remain unknown.
To evaluate whether surface-expressed or membrane associated
vimentin interacted specifically with CPMV, VOPBA (Figure 2A)
and western blotting (Figure 2B) were used to probe the
interaction. Since vascular endothelial cells are known to
internalize CPMV in vivo [13], enriched plasma membrane
proteins isolated from HUVEC were used as a positive control
(lane 1), along with HeLa and KB tumor cells (lanes 2 and 3) [21].
All cells contained the 54 kD band when probed with CPMV
particles by VOPBA (Figure 2A). Significant signal could be
observed even when incubating the virus with membrane for as
little as 5 minutes. Mouse embryo fibroblasts derived from
knockout mice lacking the vimentin gene (vim
2/2, MFT-16; lane
5) [34,35] were negative for the 54 kD CPMV-interacting band,
while membranes isolated from control vim
+/+ fibroblasts (MFT-6;
lane 4) contained the 54 kD protein and bound CPMV by
VOPBA. CPMV also bound to purified recombinant vimentin
protein (lane 7), which migrated at the expected molecular weight.
Expression of vimentin in the cell lines as detected by western blot
using anti-vimentin antibodies (Figure 2B) correlated directly with
binding of CPMV in VOPBA. CPMV capsid proteins were also
included on the gels (Figure 2A, lane 6) as a positive control in the
VOPBA for detection by CPMV-specific polyclonal antibodies. As
expected CPMV capsid proteins did not react with anti-vimentin
antibodies in the western (Figure 2B, lane 6; in addition, a loading
control for the VOPBA and western blot samples is provided in
Figure S1). Together these results demonstrate that vimentin is
present in the enriched plasma membrane fraction of human cells
and binds directly to CPMV.
The specificity of the vimentin-CPMV interaction was further
probed in ELISA format. Purified protein (vimentin, BSA, or no
protein control) was coated on ELISA plate wells overnight, and
then incubated with varying concentrations of purified CPMV
particles for one hour, followed by anti-CPMV polyclonal
antibody and an alkaline-phosphatase conjugated secondary
antibody (Figure 2C). CPMV bound specifically to vimentin
immobilized on the plates at an EC50 of 3.72 nM of CPMV.
Binding affinities that have been established for other picornavi-
rus-receptor interactions range from 100 nM to 10 mM [36–38]. It
is important to note that the 3.72 nM value does not represent the
KD of the CPMV-vimentin interaction, because ELISA assay does
not rule out the role of avidity in binding. Nevertheless, this
experiment further demonstrates a direct and specific interaction
between CPMV and vimentin. CPMV binding could also be
competed by vimentin-specific antibodies (Figure S2).
The capacity of cell surface-expressed vimentin to mediate
interactions with CPMV was further probed by flow cytometry at
37uC.CellswereincubatedwithCPMVfor30 minutes,fixed,andthe
amount of associated CPMV was detected with a CPMV-specific
polyclonal antibody. HeLa and MFT-6 vim
+/+ cells were capable of
bindingorinternalizingCPMV,whileMFT-16vim
2/2cellscouldnot
(Figure 3). Since CPMV does not replicate in mammalian cells, the
v i r u sd e t e c t e dr e p r e s e n t si n p u tv i r u sp a r t i c l e so n l y .I no r d e rt o
determine whether complementing vimentin expression in MFT-16
vim
2/2 cells would increase the CPMV interaction, these cells were
transfectedwithvimentincDNA.AlthoughMFT-16vim
2/2cellshad
low transfection efficiencies (ranging from 0.1 to 8.0% of cells using a
GFP-reporter plasmid, not shown), in the cell population that was
transfectedwithvimentin,astatisticallysignificant(p=0.036)increase
in CPMV binding or uptake was observed when compared to mock-
transfected MFT-16 cells. On average 1.21% of vimentin-transfected
MFT-16 vim
2/2 cells were CPMV-positive (data not shown). For
comparison, under identical conditions 5.36% of mock-transfected
HeLa cells were CPMV positive (data not shown). Together these
results demonstrate that the lack of CPMV binding observed in
vimentin-null cells can be complemented by vimentin expression.
To further test the specificity of CPMV for surface-expressed
vimentin in cells, antibody-blocking studies were performed. HeLa
cells were incubated with various vimentin domain-specific
antibodies at varying concentrations for 30 minutes, followed by
a 30-minute incubation with CPMV under the identical growth
conditions, and CPMV detected as described before. Anti-
vimentin monoclonal antibody V9 that targets the tail domain
was best at reducing CPMV binding, however, all antibodies did
provide some blocking of CPMV binding or entry (Table 2). This
inhibition is not complete, suggesting that either the monoclonal
or polyclonal antibodies do not bind directly to the CPMV-
interacting domains, that additional cell-surface interactions
participate in CPMV binding, or that particular domains of
vimentin may be more surface-exposed than other domains.
To further correlate CPMV uptake with surface-vimentin
expression in cell culture, HeLa cells were examined for surface
vimentin by confocal microscopy and flow cytometry. Surface
vimentin staining (Figure 4A) was shown to be markedly distinct
from controls (Figure 4B and 4C) and internal vimentin staining
(Figure 4D). The surface vimentin expression pattern observed in
HeLa cells is virtually identical to confocal observation of surface
vimentin expression previously reported in macrophages [29].
Fixation and staining procedures to verify cell surface and cytosolic
staining were verified through the ability to detect b-COP, an
intra-Golgi transport marker (Figure S3). Approximately 50% of
HeLa cells exhibited surface vimentin expression by confocal
microscopy, and surface vimentin expression was also quantified
Figure 1. Strategy for identification of CPMV binding protein
(CPMV-BP). (A) Plasma membrane enriched fractions isolated from
BalbCl7 cells (run on SDS-PAGE gel and visualized with SimplyBlue). (B)
Enriched plasma membranes were purified over concanavalin A- (to
exclude glycoproteins) and CPMV- sepharose columns. (C) CPMV-
sepharose bound material separated on SDS-PAGE gel (visualized with
SimplyBlue). *=CPMV-BP, L=CPMV large subunit, S=CPMV small
subunit. (D) CPMV-BP band (*) was excised from gel and identified
through LC-MS/MS.
doi:10.1371/journal.ppat.1000417.g001
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vimentin antibody (Figure S4). These data correlated with CPMV
binding or uptake by flow cytometry (Figure 4E). CPMV-positive
cells were observed within the surface-vimentin-expressing popu-
lation in FACS (41.3% of the total population), although not all of
these cells interacted with significant quantities of CPMV. The
apparent CPMV binding of a few cells expressing surface vimentin
at low levels was attributed to background staining (Figure S5).
Since we do not fully understand the expression, display,
function, and availability of surface vimentin or its CPMV binding
epitope it is difficult to hypothesize why some surface vimentin
expressing cells are not also positive for CPMV. Nevertheless it is
clear that surface vimentin is a prerequisite for CPMV interactions
at the cell surface.
The interaction between CPMV and surface vimentin was then
examined in animals. We first confirmed our previous results that
CPMV interacts specifically with endothelial cells in vivo by
staining with the CD31 marker. To this end, a mouse was
intravenously injected with CPMV-A555, and after one hour the
mouse was anesthetized, the aorta perfused with PBS and
removed. The freshly isolated aorta was then incubated with
antibodies recognizing the endothelial marker CD31/PECAM ex
vivo, and under fluorescent microscopic observation there was
strong co-localization between the CD31-expressing endothelial
cells and CPMV (Figure S6).
Next, studies to co-localize CPMV and surface vimentin were
performed. It had previously been suggested that vimentin is
expressed on the lumenal surface of vascular endothelial cells, in
Figure 2. CPMV virions bind specifically to vimentin. (A) VOPBA and (B) a-vimentin western blot of enriched plasma membrane isolates of the
following samples 1=HUVEC, 2=HeLa, 3=KB, 4=MFT-6 vim
+/+, 5=MFT-16 vim
2/2; 6=purified CPMV particles, 7=recombinant vimentin protein.
(C) Proteins were immobilized on ELISA plate, incubated with CPMV in varying molar concentrations and probed for CPMV attachment through
antibody detection. Immobilized proteins were vimentin (squares), BSA (triangles) and no protein (open circles). Bars represent mean+/2s.d. of
triplicate samples.
doi:10.1371/journal.ppat.1000417.g002
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antibody (although the specificity of this antibody for vimentin is
controversial) [31]. Because the expression of murine vimentin is
not efficiently recognized by the V9 mAb, we used rats for our
studies to co-localize vimentin and CPMV in vivo. In order to
focus on surface vimentin displayed on the lumenal surface of
vascular endothelium rather than cytosolic vimentin, cylinder-
shaped rat aorta segments were excised, and prior to sectioning
were incubated with CPMV-A555 or V9 mAb, washed, and then
embedded in OCT medium and 10 mm cryosections prepared.
The sections were then stained with a secondary anti-mouse
antibody. The expression of vimentin was observed on the lumenal
surface of aortic endothelium, and co-localized with CPMV
binding (Figure 4F–J, and Figure S7). The colocalization of
CPMV and vimentin in vessels correlated with the observed
vascular endothelial uptake of CPMV in vivo (Figure S6 and [13]).
Specificity of the staining procedure was also confirmed (Figure
S8). There was no CPMV colocalization outside of the endothelial
cell marker (Figure S6), or outside the surface vimentin expressing
cells (Figure 4F–J). Taken together, the CPMV colocalization with
vascular endothelium, the CPMV interaction with living vascula-
ture shown previously through intravital imaging [13], and our
current results indicating that surface vimentin facilitates this
interaction, illustrates that endothelial cell targeting of CPMV is
mediated via vimentin.
Discussion
Together these studies identify the 54 kD protein that mediates
binding of CPMV in mammalian cells as surface vimentin. These
results demonstrate that CPMV is a useful nanoparticle probe for
examining the expression of surface vimentin on endothelial cells
and circulating cells in vivo. The ability of CPMV to efficiently
visualize tumor neovasculature and differentiate arterial from
venous tissues [13] may now be attributed to upregulation of
surface vimentin. Upregulation of cytosolic vimentin has long been
associated with tumor progression and metastasis during the
epithelial-mesenchymal transition (EMT) [39], however our
findings suggest that increased surface vimentin is also a key
feature of tumor endothelium as evident by ability of CPMV to
preferentially image these areas [13] and may signal a role for
surface vimentin in tumor metastasis or invasion, in addition to
cellular adhesion and stress. The use of CPMV as a natural
endothelial probe may also extend into the investigation of other
vascular diseases such as atherosclerosis. Finally, the CPMV-
vimentin interaction may provide a tool for understanding the
display and internalization of surface-expressed vimentin, the
mechanism and function of which is currently unknown.
It is also not clear whether the CPMV-vimentin interaction is
important for virion movement in its host plant species. CPMV is
not known to be dependent on cellular receptors for cell-cell
spread; rather like many plant viruses CPMV encodes a
movement protein (MP) that mediates movement of virus particles
within leaf tissue via the plasmodesmata [40,41]. The mechanism
of CPMV loading and unloading from the plant host’s vascular
elements is not understood [42]. Access to plant vascular tissues
may be mediated by direct virus capsid-cellular interactions
independent of MP, and intermediate filament-like proteins may
play a role in the vascular tropism of CPMV in plants.
Interestingly the animal picornavirus TMEV has also been
shown to interact directly with vimentin using a similar VOPBA
strategy with isolated enriched plasma membrane proteins [43].
Coupled with our findings, this further strengthens the link
between animal and plant picornaviruses not only structurally and
genetically, but with regard to attachment mechanisms as well.
The original characterization of CPMV bioavailability was
performed following oral administration of virus or infected
leaves, whereby virus was subsequently found in the blood
circulation [16]. The stability of CPMV in the gastrointestinal
tract and its subsequent systemic biodistribution provides an
opportunity for interactions between CPMV and mammalian cells
following ingestion [16]. While there is no evidence for CPMV
replication in mammalian or avian cells, the conserved interaction
Figure 3. Cell-surface expression of vimentin promotes inter-
action with CPMV. Flow cytometry of surface vimentin-expressing
cells HeLa and MFT-6 vim
+/+, and vimentin negative MFT-16 vim
2/2 cell
types incubated with (black bars) and without (white bars) 10
5 CPMV
particles per cell for 30 minutes at 37uC in respective growth media.
Bars represent mean+/2s.d. of triplicate samples.
doi:10.1371/journal.ppat.1000417.g003
Table 2. Ability of anti-vimentin antibodies to block CPMV interaction with HeLa cells in vitro (mean6s.d.).
Antibody
Polyclonal or
Monoclonal
Vimentin Epitope
Region
Percent of CPMV Uptake
Blocked at 1:500 dilution
Percent of CPMV Uptake
Blocked at 1:100 dilution
Percent of CPMV Uptake
Blocked at 1:50 dilution
H84 Polyclonal Head 27.8629 1365.6 12615
3B4 Monoclonal Rod 21.1636 33620 36614
V4630 Polyclonal Rod, Tail 27619 38611 42627
V9 Monoclonal Tail 2.868.0 48610 6067.9
doi:10.1371/journal.ppat.1000417.t002
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plant, insect and animal picornaviruses, supports the hypothesis
that the picornavirus superfamily of viruses evolved from a
common ancestor. The identification of conserved mechanisms of
attachment and entry also point to a possible mode of cross-
kingdom transmission.
Other roles for vimentin during the picornavirus replication
cycle include reorganization of cytosolic vimentin into cages that
enclose autophagic vesicles at intracellular replication centers by
TMEV and poliovirus [43–45]. The picornavirus encephalomyo-
carditis virus (EMCV) further induces an autoimmune response
against vimentin after infection [46].
In addition to picornaviruses, several other pathogens use
vimentin as a component of the cellular attachment mechanism,
suggesting a conserved role for surface vimentin as a more general
attachment factor for pathogen entry. These include mammalian
porcine reproductive and respiratory syndrome virus (PRRSV),
which uses surface vimentin for cellular entry [47]. Bacteria such
as Escherichia coli also interact with surface vimentin to mediate
cellular attachment via the invasion factor IbeA [48]. Finally,
upregulation of surface vimentin on injured skeletal muscle cells
was recently shown to be a ligand for attachment of group A
streptococci (GAS) and was associated with streptococcal toxic
shock syndrome [32]. Together these studies highlight an
increasingly important role for surface vimentin as a conserved
component of pathogen attachment and internalization pathways,
and suggest that disruption of these interactions may serve as
broad-spectrum antimicrobial strategies.
Materials and Methods
Cell Culture
HeLa cells were grown and maintained in DMEM media
supplemented with 7% heat-inactivated fetal bovine serum
(DFBS), 50 units/mL penicillin, 50 units/mL streptomycin, and
2 mM L-glutamine. Murine Balb Cl 7 cells were grown and
maintained in MEM media supplemented with 7% DFBS, 50
units/mL penicillin, 50 units/mL streptomycin, and 2 mM L-
glutamine. HUVEC cells were grown and maintained using
Endothelial Cell Growth Media Bulletkit (Cambrex). KB cells
were grown and maintained in MEM media supplemented with
10% DFBS, 50 units/mL penicillin, 50 units/mL streptomycin,
and 2 mM L-glutamine. MFT-6 and MFT-16 cells (a generous gift
from Dr. Robert Evans, University of Colorado Health Sciences
Center) were grown and maintained in 1:1 DMEM and F-12
HAMS medias supplemented with 50 units/mL penicillin, 50
units/mL streptomycin, 2 mM L-glutamine, and 5% and 9%
DFBS respectively. All cells were grown at 37uCi n5 %C O 2/95%
air humidified atmosphere.
Viruses
CPMV was grown, isolated, and when needed fluorescently
labeled with AlexaFluor 488 or AlexaFluor 555 carboxylic acid,
succinimidyl ester (Invitrogen) as described previously [13].
Labeled virus was calculated to have 65 AlexaFluor 488 molecules
per virion or 55 AlexaFluor 555 per virion.
Antibodies
Rabbit polyclonal anti-CPMV antibody was generated as
previously described [21]. Antibodies against vimentin were rabbit
polyclonal H-84 (Santa Cruz Biotechnology), mouse monoclonal
3B4 (Chemicon), whole goat antiserum V 4630 (Sigma) and mouse
monoclonal IgG1 V9 (Sigma). Primary rat monoclonal anti-
PECAM (CD31) was purchased from BD Biosciences. Secondary
antibodies were donkey anti-goat IgG-HRP (Santa Cruz Biotech-
nology), goat anti-rabbit IgG-HRP (Pierce), goat anti-mouse
Alexafluor 488 conjugated antibody (Invitrogen), goat anti-rabbit
Alexafluor 488 conjugated antibody (Invitrogen), goat anti-mouse
Alexafluor 647 conjugated antibody (Invitrogen) and goat anti-rat
Alexafluor 488 conjugated antibody (Invitrogen). IgG1 isotype
control waspurchased from BD Biosciences and donkey biotinylated
anti-rabbit IgG antibody from Amersham Biosciences.
Enriched Plasma Membrane Protein Isolations
Cell lines were propagated and enriched plasma membranes
isolated and stored in 10 mM Tris/HCl, pH 8.0, 10 mg/mL
aprotinin and leupeptin (Roche), and 0.5% n-octyl-b-D-glycopyr-
anoside (Sigma) as described previously [21]. The surface
membrane-impermeable biotinylation of cells surface proteins
and isolation was performed using the Cell Surface Protein
Isolation Kit (Pierce) as directed by the manufacturer.
Figure 4. Correlation of vimentin surface expression and CPMV binding in cells and vasculature. (A) Surface vimentin expression on
HeLa cells detected by V9 IgG1 antibody. Bar=10 mm. (B) IgG1 isotype control. (C) Secondary antibody only. (D) Cytosolic vimentin expression in
permeabilized HeLa cells detected by V9 IgG1 antibody. (E) Surface vimentin expression on HeLa cells (X-axis), and ability to interact with CPMV (Y-
axis) were analyzed by flow cytometry. (F–J) CPMV and surface vimentin co-localize on the lumenal surface of rat aorta. Freshly isolated rat aorta was
incubated with CPMV and vimentin antibodies ex vivo, and then 10 mm cryosections made and stained with secondary antibodies for confocal
microscopy. F: co-localization of CPMV and vimentin on aortic endothelium. *=aorta lumen. G–J: individual detection and co-localization of CPMV
and vimentin. Green=vimentin (panel F, G, I); red=CPMV (panel F, H, I); co-localization of CPMV and vimentin signal=white (F, I, J), where J shows
only co-localized signal. Blue=DAPI stain for nuclei. Bar=100 mm (F) and 25 mm (G) respectively.
doi:10.1371/journal.ppat.1000417.g004
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To create CPMV-sepharose beads, 100 ml of NHS-activated
Sepharose 4 Fast Flow (Amersham Biosciences) beads were
washed with 1 mL of 1 mM HCl for 5 minutes at 4uC. HCl
solution was removed and 18 mL of 0.1 M KPO4, pH 7.0 was
added. 2 mL of 15 mg/mL CPMV in 0.1 M KPO4, pH 7.0 was
added to NHS-activated sepharose already in solution. This
mixture was rotated slowly on a LabQuake rotator (Cardinal
Health) at room temperature for 2 hours. The mixture was
centrifuged for 2 minutes at 100 g to pellet beads and remove
excess solution. 20 mL of 0.1 M Tris/HCl, pH 8.0 was then
added and put on slow rotation using the LabQuake rotator
overnight at room temperature to hydrolyze unreacted NHS-
esters. The resultant CPMV-sepharose beads were then exten-
sively washed with 0.1 M KPO4, pH 7.0.
Western and VOPBAs
10 mg of enriched plasma membrane protein isolates, from
respective cell lines, were run on 4–12% Bis-Tris 1.0 mm
NuPAGE gel (Invitrogen) unless otherwise specified. Proteins
samples were then transferred electrophoretically to Immobilon-P
transfer membranes (Millipore). Transfer membranes were then
blocked overnight with 5% w/v milk solution. The membranes
were then washed 4 times for 5 minutes each with wash buffer
consisting of PBS with 0.2% Triton X-100 (Sigma). All antibodies
and viral suspensions were diluted in wash buffer. For western
blotting, samples were subject to one hour incubation with anti-
vimentin whole goat antiserum V 4630, washed 4 times with wash
buffer for 5 minutes each, then incubated one hour with donkey
anti-goat IgG-HRP, washed 4 times with wash buffer for
5 minutes each, visualized with chemiluminescence detection
(SuperSignal; Pierce) and exposed to CL-XPosure film (Pierce).
For VOPBA, samples were subject to one hour incubation with
10 mg/mL CPMV in 1% milk solution with 5% glycerol, washed 4
times with wash buffer for 5 minutes each, then subject to one
hour incubation with anti-CPMV polyclonal antibody, washed 4
times with wash buffer for 5 minutes each, then incubated one
hour with goat anti-rabbit IgG-HRP, washed 4 times with wash
buffer for 5 minutes each, visualized with chemiluminescence
detection (SuperSignal; Pierce) and exposed to CL-Xpossure film
(Pierce).
Proteomic Analysis
Screen 1. Two 40 mg samples of Balb Cl 7 enriched plasma
membrane isolate was separated on a single 4–12% Bis-Tris
1.5 mm NuPAGE gel. One sample was subjected to VOPBA
analysis and the resultant CPMV reactive band seen on X-ray film
was used to target and excise the similar region of the other
sample.
Screen 2. Balb Cl 7 cell surface proteins were isolated using
the Cell Surface Protein Isolation Kit (Pierce). Four T75 tissue
culture flasks containing confluent monolayers of Balb Cl 7 were
used for isolation. The consequential surface proteins were split
into two samples, and separated on a single 4–12% Bis-Tris
1.5 mm NuPAGE gel. One sample was subjected to VOPBA
analysis and the resultant CPMV reactive band seen on X-ray film
was used to target and excise the similar region of the other
sample.
Screen 3 (sequential column chromatography). 218 mlo f
4.6 mg/mL Balb Cl 7 enriched plasma membrane isolate was
mixed with 400 ml of 0.1 M KPO4, pH 7.0. This mixture was run
over a 1 mL Concanavalin A Sepharose (Amersham Biosciences)
column, and washed with 2 mL 0.1 M KPO4, pH 7.0. The flow
through was then incubated with 100 ml of CPMV-sepharose
beads for 10 minutes at room temperature. The CPMV-sepharose
beads were then washed with 200 column volumes of 0.1 M
KPO4, pH 7.0. CPMV-sepharose beads were drained, SDS-
PAGE reducing buffer added, boiled at 95uC for ten minutes, split
into two equal volumes, and each separated on single 4–12% Bis-
Tris 1.5 mm NuPAGE gel. One sample was subject to VOPBA to
identify capture of CPMV-BP, and the other visualized through
SimpleBlue Stain (Invitrogen). CPMV-BP band was excised.
Chromatography and Mass Spectrometry
The excised gel bands for proteomic analysis were treated with
10 mM dithiothrietol to reduce disulfide linkages. Alkylation was
performed with 55 mM iodoacetamide (Sigma-Aldrich) before
digestion with trypsin (Promega) over night at 37uC using an
estimated (1:30) enzyme to substrate ratio in 50 mM ammonium
bicarbonate. The liquid chromatography separation was per-
formed on a laser pulled 100 mmI DC 18 column with a tip of
,5 mm that is also used as a nanoelectrospray emitter. An Agilent
1100 HPLC system equipped with a nanopump was used to
perform the gradient elution at a flow rate of 300 nL/min with
0.1% formic acid/acetonitrile as the mobile phases, from 5% to
35% acetonitrile in 100 minutes, then up to 90% acetonitrile for
15 minutes. The MS/MS analysis was performed on a LTQ
linear ion trap mass spectrometer (Thermo Electron Corp.), as
well as an Agilent LC/MSD Trap ion trap mass spectrometer.
Data-dependent scanning was used to maximize the number of
peptides sequenced in the highly complex mixture. This mode of
operation uses preset criteria to select unique peptides on-the-fly
for undergoing MS/MS. Over 10,000 MS/MS spectra were
obtained during the runs. These were searched using MASCOT
(Matrix Science, Limited) with the Sprot protein database. To
improve searching efficiency, taxonomic category was limited to
rodent proteins. Only peptides producing good quality fragmen-
tation spectra and scoring higher than the threshold required for
95% confidence level for Mascot were used for protein
identification. A protein identification was only validated if two
or more peptides were identified with ion scores needed for 95%
confidence level.
ELISA
One mg of vimentin, BSA or no protein at all, was suspended in
150 mL 0.1 M KPO4 pH 7.0, was immobilized overnight in 96-
well Immulon 2 HB plates (Thermo). During the immobilization,
plates were kept at room temperature and in buffer humidified
containers. The next morning the protein solutions were discard
and wells blocked for 2 hours at room temperature with 300 mLo f
3% milk solution in 0.1 M TBS pH 7.3 with 0.05% Tween 20. All
washes were completed with 0.1 M TBS pH 7.3 with 0.05%
Tween 20, all viral and antibody dilutions were made in 150 mL
0.1 M KPO4 pH 7.0 and all incubations took place at room
temperature unless specifically stated. After blocking wells they
were washed and appropriate molar concentrations of virus were
added to each well. For ‘‘no protein’’ wells the same amount of
virus was used as was used in the vimentin wells. Viral incubations
lasted 1 hour, was followed by 3 washes and 1 hour incubation
with rabbit anti-CPMV polyclonal antibody. This was followed by
3 washes and 1 hour incubation with donkey biotinylated anti-
rabbit IgG antibody. Then this was followed by 3 washes and
1 hour incubation with streptavidin-alkaline phosphatase (Amer-
sham Bioscience). Another 3 washes were completed and p-
nitriphenyl phosphate (Sigma) was incubated for 20 minutes at
37uC or until the negative control started to barely change color.
The reaction was stopped by addition of 2N NaOH for
10 minutes at room temperature. Signal was recorded at
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Devices). All experiments were repeated in triplicate with average
and standard deviation reported.
Flow Cytometry
To detect CPMV interactions cells were dissociated from
growth flask using Hanks’-Based, Enzyme Free, Cell Dissociation
Buffer (Invitrogen), counted and resuspended in their respective
growth media. These cells were then aliquoted into 96-well V-
bottom plates. Plates were spun to collect cells after each addition
of virus, fixative, antibody or washing. Cells were then incubated
with wildtype CPMV in a ratio of 1610
5 virions per cell (V/C) for
30 minutes at 37uC. Cell were washed three times with FACS
buffer consisting of PBS, 1 mM EDTA, 25 mM HEPES and 1%
FBS at pH 7.0. Cells were fixed for 15 minutes with 2%
formaldehyde in PBS and then washed three times with FACS
buffer. Cells were then washed once with FACS buffer containing
0.5% saponin (Sigma) also called permeablization buffer (PB).
Cells were then incubated with rabbit polyclonal anti-CPMV
antibody diluted in PB for one hour at room temperature and then
washed three times with PB. Secondary goat anti-rabbit Alexafluor
488 conjugated antibody was diluted in PB and incubated with the
cells for one hour at room temperature in the dark. Cells were
washed a final three times with FACS buffer, fluorescence
quantitated with a LSR-II Digital Flow Cytometer (BD Biosci-
ences) and data analyzed used FlowJo software (Tree Star Inc.).
For antibody blocking experiment after HeLa cells were aliquoted
they were incubated with varying concentrations (1:50, 1:100,
1:500 or no antibody) of H-84, 3B4, V4630 or V9 antibody for
30 minutes at 37uC, then addition of AlexaFluor 488 labeled virus
for 30 minutes at 37uC and procedure continued as discussed
above. For in vitro CPMV binding or internalization and surface
vimentin staining flow cytometry the same procedure was used
except: AlexaFluor 488 labeled virus was used, no PB was used
and surface vimentin analyzed through use of V9 anti-vimentin
monoclonal antibody in place of rabbit polyclonal anti-CPMV
polyclonal antibody and secondary goat anti-rabbit Alexafluor 488
conjugated antibody replaced with goat anti-mouse Alexafluor 647
conjugated antibody. For surface vimentin staining in Figure S4
cells were fixed, not permeablized, and staining using V9 anti-
vimentin or mouse IgG1 isotype control and goat anti-mouse
Alexafluor 647 conjugated antibody as discussed above. For each
experiment at least 10,000 events were collected and were
repeated in at least triplicate with average and standard deviations
calculated in Microsoft Excel and reported.
MFT-16 (Vimentin 2/2) Transfection
The night beforetransfection500,000cellswereseededin2 mLof
growth media in 6-well plates and grown overnight to 90–95%
confluence at 37uCi na5 %C O 2/95% air humidified atmosphere.
For each well of cells 4 mg of pCMV-SPORT6-vimentin (Open
Biosystems), a vimentin plasmid with CMV promoter, or no DNA
(mock transfection) was diluted in 250 ml of transfection media
(growth media without DFBS or antibiotics). For each well 10 mlo f
Transfectin (Biorad) was diluted in 250 ml of transfection media, and
incubate at room temp for 5 minutes. The diluted DNA and
Transfectin was combined, mixed gently, and incubated at room
temperature for 20 minutes. Growth media was aspirated from cells,
and cells washed twice with PBS. The combined DNA and
Transfectin was added dropwise to the well of cells and returned to
37uCi na5 %C O 2/95% air humidified atmosphere. After 4 to
6 hours DNA/Transfectin mixture was aspirated off cells, cells
washed twice with PBS, and 2 mL of growth media added to cells.
Cells were returned to 37uCi na5 %C O 2/95% air humidified
atmosphere for 24 hours. Cells were removed from wells using
Hanks’-Based, Enzyme Free, Cell Dissociation Buffer, counted and
500,000cellsplacedinwellsofaV-bottom96-wellplate.InV-bottom
wells cells were then incubated with wildtype CPMV at 5610
5 V/C
or no virus for 2 hours. CPMV interaction was measured using the
flow cytometry procedure listed above. Transfection efficiency varied
per experiment ranging from 0.1 to 8% efficiency. Transfection
efficiency was measured through permeablization of cells and
identification of vimentin expression using V9 anti-vimentin mono-
clonal antibody and goat anti-mouse Alexafluor 647 conjugated
antibody while using PB buffer in flow cytometry preparation listed
above. All transfections were repeated in triplicate.
Confocal Microscopy of HeLa Vimentin Expression
HeLa cells were seeded in a 12-well plate containing 12 mm
sterile glass cover slips at 5610
4 cells/well and grown for 48 hours in
RPMI1640 medium containing 10% DFBS, 50 units/mL penicillin,
50 units/mL streptomycin, and 2 mM L-glutamine at 37uCi na5 %
CO2/95% air humidified atmosphere. On the day of the
experiment, cells were fixed using 3% paraformaldehyde, 0.3%
gluteraldeyde, 1 mM MgCl2 in PBS for 10 minutes. After 4 washes
with PBS buffer, only the cells that were to be intracellularly stained,
were permeabilized using 0.2% Triton X-100 in PBS for 2 minutes.
Non-specific binding was blocked by incubating the cells in 5% goat
serum inPBS for 1 hour. Incubations with either mouse monoclonal
anti-vimentin V9 antibody, rabbit polyclonal anti-b-COP (Affinity
Bioreagents) or purified mouse IgG1 isotype control were performed
at room temperature for 45 minutes with gentle agitation. Unbound
antibody was then removed by washing four times with PBS. Goat
anti-mouse IgG AlexaFluor 555 conjugated antibody (Invitrogen) or
goat anti-rabbit IgG AlexaFluor 488 conjugated antibody (Invitro-
gen) were added appropriately in 1% goat serum in PBS, and cells
were gently agitated for a further 45 minutes. During the last five
minutes of secondary antibody incubation, cell nuclei were stained
by adding 100 mLo f4 9,6-diamidino-2-phenylindole (DAPI 1:1000
dilution in water). Cells were then washed 4 times using PBS and
cover slips covered with cells were mounted on slides using Vecta
Shield mounting medium (Vector Laboratories). Cells were imaged
using a Bio-Rad (Zeiss) Radiance 2100 Rainbow laser scanning
confocal microscope equipped with 606oil-immersion objective.
Ex Vivo Rat Aorta Study
Animals used in this study were Harlan Sprague-Dawley male
rats obtained from Charles River Inc. Animals were used in
compliance with Institutional Animal Care and Use Committee
(IACUC) approved protocols. On the day of the experiment, rats
were anesthetized and the aorta perfused with ice-cold PBS for
10 minutes via the left ventricle. The aorta was then removed by
cutting off minor branching arteries and rinsed in ice-cold PBS to
remove adhering blood components. Aorta transverse segments
were obtained and incubations with either mouse monoclonal
anti-vimentin V9 antibody, purified mouse IgG1 isotype control,
CPMV labeled with Alexafluor 555 (20 mg), or a combination of
V9 and labeled virus were performed at 4C for 1 hr in the dark.
V9 antibody was diluted 1 to 40 in 2% natural goat serum, 1%
BSA in PBS. Incubation with IgG1 isotype control was performed
so that the same amount of antibody as for V9 was used. The
segments were then washed 3 times with ice-cold PBS in the dark
and embedded in OCT (Tissue-Tek). 10 mm sections were
obtained using a Leica CM1850 cryostat, collected on glass slides
and fixed in ice-cold 95% ethanol for 30 minutes at 4C. After
rinsing the slides with PBS, goat anti-mouse Alexafluor 488
conjugated antibody was added for 1 hr in the dark. In the last ten
minutes of secondary antibody incubation, nuclei were stained
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washed 4 times with PBS and mounted using Vecta Shield
mounting medium. Aorta segments were imaged using a Bio-Rad
(Zeiss) Radiance 2100 Rainbow laser scanning confocal micro-
scope equipped with 606oil-immersion objective.
In Vivo Mouse Aorta Study
C57Bl/6J mice (rodent breeding colony, TSRI) were used in
accordance with IACUC approved protocols. On the day of the
experiment, mice were inoculated intravenously using 500 mgo f
CPMV labeled with Alexafluor 555. After 1 hour the mice were
anesthetized and the aorta perfused with ice-cold PBS for
10 minutes via the left ventricle. The aorta was then removed
by cutting off minor branching arteries and rinsed in ice-cold PBS
to remove adhering blood components. Aorta transverse segments
were obtained and embedded in OCT. 10 mm sections were
obtained using a Leica CM1850 cryostat, collected on glass slides
and fixed in ice-cold 95% ethanol for 30 minutes at 4C. After
rinsing the slides with PBS, blocking was performed using 10%
natural goat serum in PBS for 30 minutes. The sections were then
incubated with PECAM (CD31) primary antibody in 5% goat
serum in PBS. After 1 hour, slides were washed four times in PBS.
Goat anti-rat Alexafluor 488 conjugated secondary antibody was
then added in 5% goat serum in PBS. In the last ten minutes of
secondary antibody incubation, nuclei were stained using 49,6 -
diamino-2-phenylindole (DAPI). Slides were then washed 4 times
with PBS and mounted using Vecta Shield mounting medium
(Vector Laboratories). Aorta segments were imaged using a Bio-
Rad (Zeiss) Radiance 2100 Rainbow laser scanning confocal
microscope equipped with 606oil-immersion objective.
Supporting Information
Figure S1 Loading control for samples in Figure 2A and 2B,
CPMV VOPBA and anti-vimentin western blot of enriched
plasma membrane isolates. Lanes: 1=HUVEC, 2=HeLa,
3=KB, 4=MFT6 vim+/+, 5=MFT16 vim2/2, 6=purified
CPMV particles, 7=recombinant vimentin protein. Molecular
weight standards are noted at left.
Found at: doi:10.1371/journal.ppat.1000417.s001 (0.07 MB PDF)
Figure S2 Anti-vimentin monoclonal antibody V9 inhibits
CPMV binding to vimentin in both VOPBA and in ELISA format.
(A) Using the VOPBA format as shown in Figure 2A, HeLa cell
membrane-enriched fractions were separated on SDS-PAGE and
transferred to membranes as described in Materials and Methods.
Membranes were cut into strips and separately were incubated for
one hour with V9 antibody (5.0 mg/mL), mouse IgG1 isotype
control (5.0 mg/ml), or no antibody, prior to a five minute
incubation with CPMV, and the VOPBA procedure continued as
described in Materials and Methods. (B) Using the ELISA format as
shown in Figure 2C, 0.9 mg of purified vimentin protein were
immobilized per well, then wellswereincubated for two hours with a
3% milk solution to block nonspecific binding, wells were extensively
washedthen incubatedforone hourwith anti-vimentinV9or mouse
IgG1 isotype control antibody (ratio on x-axis indicates molar ratio
of antibody to immobilized vimentin used). Again wells were
extensively washed then incubated with a 2-fold molar excess of
CPMV,andtheELISAprocedurecontinuedaspreviouslydescribed
for detection of CPMV binding in Figure 2C. Bars represent
mean+/2S.D. of duplicate samples. * indicates p-value,0.05.
Found at: doi:10.1371/journal.ppat.1000417.s002 (0.19 MB PDF)
Figure S3 Establishing specificity of surface and internal staining
of HeLa cells using confocal microscopy. (A) Surface HeLa
expression of vimentin. (B) Surface HeLa expression of beta-COP.
(C) Internal HeLa expression of vimentin. (D) Internal HeLa
expression of beta-COP. Bar=25 mm.
Found at: doi:10.1371/journal.ppat.1000417.s003 (0.10 MB PDF)
Figure S4 Surface vimentin expression on HeLa cells analyzed
by flow cytometry. Samples of HeLa cells were stained with
secondary antibody only (red histogram), mouse IgG1 isotype
control (blue histogram) or V9 anti-vimentin (IgG1, green
histogram). Marker indicates percentage of total population of
cells that expressed surface vimentin compared to 0.19% for
isotype control.
Found at: doi:10.1371/journal.ppat.1000417.s004 (0.10 MB PDF)
Figure S5 Controls for flow cytometry analysis of CPMV
binding and vimentin expression on HeLa cells. HeLa cells were
subjected to one hour incubation with labeled CPMV under
growth conditions or surface vimentin staining. (A) Cells only. (B)
Secondary antibody only. (C) After one hour incubation with
labeled CPMV. (D) Vimentin surface staining of HeLa cells.
Found at: doi:10.1371/journal.ppat.1000417.s005 (0.14 MB PDF)
Figure S6 CPMV and CD31/PECAM (an endothelial marker)
co-localize on the lumenal surface of mouse aorta. An adult
C57Bl6J mouse was intravenously inoculated with Alexafluor 555-
labeled CPMV. After one hour the mouse was anesthetized, aorta
perfused with PBS and removed. From the freshly isolated aorta
segments 10 mm cryosections were prepared and then cryosections
were stained with CD31/PECAM antibodies. Blue=nuclei
(DAPI), green=CD31/PECAM (A and C), red=CPMV (B and
C), white=colocalization (C and D), *=lumen, and scale
bar=25 mm.
Found at: doi:10.1371/journal.ppat.1000417.s006 (0.11 MB PDF)
Figure S7 Additional examples of CPMV and surface vimentin
co-localization on the lumenal surface of rat aorta evaluated by
confocal microscopy. (A–E) Freshly isolated rat aorta was
incubated with CPMV and vimentin antibodies ex vivo, and
10 mm cryosections made. Blue=DAPI, green=vimentin,
red=CPMV, white=colocalization, *=vessel lumen, and
bar=100 mm (A) and 25 mm (B) respectively.
Found at: doi:10.1371/journal.ppat.1000417.s007 (0.10 MB PDF)
Figure S8 Establishing specificity of CPMV and vimentin
staining in rat aorta via fluorescence confocal microscopy. Rat
aortic segments incubated ex vivo with labeled CPMV or vimentin-
specific antibodies were cryosectioned and stained with secondary
antibodies. (A) CPMV. (B) Monoclonal anti-vimentin antibody.
(C) Monoclonal isotype control. Bar=10 mm, *=lumen.
Found at: doi:10.1371/journal.ppat.1000417.s008 (0.09 MB PDF)
Table S1 Protein name, accession number, number of peptides
identified, and sequence coverage of all proteins found in
proteomic analysis 1–3.
Found at: doi:10.1371/journal.ppat.1000417.s009 (0.04 MB XLS)
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